The effect of clomiphene citrate on osteoporosis in ovariectomized rats

Archives of Gynecology and Obstetrics

Volumn 278, Issue 2, 2008, Pages 107-114

  Uyar, Yildiz ^a,c   Koltan, Semra Oruç ^a   Pögün, Şakire ^b   Vatansever, Seda ^a   Çaglar, Hüsnü ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c NONE   (United Kingdom)

Author keywords

Clomiphene citrate; Estrogen; Ovariectomized rat; Postmenopausal osteoporosis

Indexed keywords

CLOMIFENE CITRATE; ESTRADIOL; SESAME SEED OIL;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE STRUCTURE; CALORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HISTOLOGY; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; UTERUS WEIGHT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLOMIPHENE; DISEASE MODELS, ANIMAL; ESTRADIOL; FEMALE; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 44649159962     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-007-0534-y     Document Type: Article

References (37)

1. McKinlay SM, Bigano NL, McKinlay JB (1985) Smoking and age at menopause. Ann Intern Med 103:350
2. Silverman SL, Delmas PD, Kulkami PM, Stock Jl, Wong M, Plauffe Jr (2004) Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 52(9):1543-1548
3. Gambert SR, Schultz BM, Handy RC (1995) Osteoporosis clinical fractures, prevention and treatment. Endocrinol Metab North Am 24(2):317-371
4. Riggs BL (1987) Pathogenesis of osteoporosis. Am J Obstet Gynecol 156(5):1342-1346
5. Spector TD, Cooper C, Lewis AF (1990) Trends in admissions for hip fracture is England and Wales. 1968-85. Br Med J 300:1173-1174
6. Quigley MET, Martin PL, Burnier AM, Brooks P (1987) Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156:1516
7. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 8(359):2018-2026
8. Chen L, Zeng I, Xia W, Li H, Zhou M (2000) The effect of estrogen on the restoration of bone mass and bone quality in ovariectomized rats. J Tongii Med Univ 20(4):283-6
9. Tiegs RD, Body JJ, Wahner HW, Barta J, Riggs BL, Heath H (1985) Calcitonin secretion in postmenopausal osteoporosis. New Engl J Med 312:1097
10. Million Women Study Collaborators (2003) Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362:419-427
11. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289:3243-3253
12. Kauffmann RF, Bryant HU (1995) Effective therapeutic management of the postmenopausal state will be a cornerstone in strategies for preserving or improving women's health in the 21st century. Selective estrogen receptor modulators. Drug News Perspect 8:531-539
13. Chakraborty PK, Brown JL, Ruff CB, Nelson MF, MItchell AS (1991) Effects of long term treatment with estradiol or clomiphene citrate on bone maintenance and pitüitary and uterine weights in ovariectomized rats. J Steroid Biochem Mol Biol 40(4-6):725-729
14. Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192
15. Wronski TJ, Dann LM, Scott KS, Cintron M (1989) Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45:360-366
16. Howard CV, Reed MG (1998) Unbiassed Sterology. BIOS Press, Oxford
17. Riggs BL, Melton LJ III (1992) The prevention and treatment of osteoporosis. N Engl J Med 327:620-627 [Erratum (1993) 328:65]
18. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995) Estrogen replacement therapy and fractures in older women. Study of osteoporosis fractures research group. Ann Intern Med 122:9-16
19. Maxim P, Ettinger B, Spitalny GM (1995) Fracture protection provided by long-term estrogen treatment. Osteoporos Int 5:23-29
20. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
21. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 26;283(4):485-491
22. Food and Drug Administration (2003) FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative data. Food and Drug Administration, Rockville
23. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 4;337(23):1641-1647
24. Barrett-Connor E, Cox DA, Anderson PW (1999) The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrinol Metab 10(8):320-325
25. Dhingra K (1999) Antiestrogens - tamoxifen, SERMs and beyond. Invest New Drugs 17(3):285-311
26. McDonnell DP (1999) The molecular pharmacology of SERMs. Trends Endocrinol Metab 10(8):301-311
27. Miller CP, Komm BS (2001) Targeting the estrogen receptor with SERMs. In: Dohrety AM (ed) Annual reports in medicinal chemistry. Academic Press, San Diego, pp 149-158
28. Sutherland MK, Brady H, Gayo-Fung LM, Leisten J, Lipps SG, McKie JA, O'Leary E, Patnaik N, Anderson DW, Bhagwat SS, Stein B. (2003) Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat. Calcif Tissue Int 72(6):710-716
29. Armamento-Villareal R, Sheikh S, Nawaz A, Napoli N, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R (2005) A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats. J Bone Miner Res 20(12):2178-2188
30. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145(4):1996-2005
31. Ruenitz PC, Shen Y, Li M, Liang H, Whitehead RD Jr, Pun S, Wronski TJ (1998) Specific bone-protective effects of metabolites/derivatives of tamoxifen and clomiphene in ovariectomized rats. Bone 23(6):537-542
32. GouldIng A, Lorryn Fisher (1991) Preventetive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat. J Bone Miner Res 6(11):1177-1181
33. JImenez MA, Magee DE, Bryant HU, Turner RT (1997) Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology 138:1794-1800
34. Evans G, Bryant HU, Magee DE, Sato M, Turner RT (1994) The effects of Raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134(5):2283-2288
35. Bowman AR, Sass DA, Marshall I, Ma YF, Liang H, Jee WS, Epstein S (1996) Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats. J Bone Miner Res. 11(8):1191-1198
36. Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WS, Thompson DD (1995) Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone 17(5):491-496
37. Bourrin S, Ammann P, Bonjour JP, Rizzoli R. (2002) Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 30(1):195-200